A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19 - Doi, Yohei; Hibino, Masaya; Hase, Ryota; Yamamoto, Michiko; Kasamatsu, Yu; Hirose, Masahiro; Mutoh, Yoshikazu; Homma, Yoshito; Terada, Masaki; Ogawa, Taku; Kashizaki, Fumihiro; Yokoyama, Toshihiko; et al. (Antimicrobial agents and chemotherapy, 2020)
Keywords: Adolescent; Adult; Amides - administration & dosage; Amides - adverse effects; Antiviral Agents; Antiviral Agents - administration & dosage; Antiviral Agents - adverse effects; Asymptomatic Diseases; COVID-19 - drug therapy; COVID-19 - physiopathology; COVID-19 - virology; Female; Hospitalization; Humans; Hyperuricemia - chemically induced; Hyperuricemia - diagnosis; Hyperuricemia - physiopathology; Japan; Male; Middle Aged; Prospective Studies; Pyrazines - administration & dosage; Pyrazines - adverse effects; Random Allocation; SARS-CoV-2 - drug effects; SARS-CoV-2 - pathogenicity; Secondary Prevention - organization & administration; Severity of Illness Index; Time-to-Treatment - organization & administration; Treatment Outcome; Viral Load - drug effects; Japan; COVID-19; randomized clinical trial; Avigan; antiviral therapy